TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00388388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan, hydrochlorothiazide
Description: Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan, hydrochlorothiazide
Description: Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Study: NCT00925106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex capsule
Description: Single dose 200 mg commercial Celebrex capsule
Study: NCT02186834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
Study: NCT03462082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric STN-DBS
Description: Asymmetric deep brain stimulation
Study: NCT00925106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation D1
Description: Single dose 150 mg celecoxib as formulation D1
Study: NCT00023920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study: NCT00925106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation D2
Description: Single dose 150 mg celecoxib as formulation D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation D3
Description: Single dose 150 mg celecoxib as formulation D3
Study: NCT02136758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC lifestyle modification program
Description: Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
Study: NCT01110330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream (formulation F012) (Nizoral)
Description: A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream (formulation F126)
Description: A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
Study: NCT03391024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBL Experimental Navigation System
Description: Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
Study: NCT03853538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one hemiface.
Study: NCT04749758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF treatment
Description: SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
Study: NCT02687685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact immediate
Description: Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skin to skin contact early
Description: Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
Study: NCT05878327

Intervention type: OTHER
Intervention: Thrombophilia screening
Description: No intervention. Blood is drawn for analysis.
Study: NCT04683549

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
Description: Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy.
Study: NCT03388866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mite extract sublingual immunotherapy (SLIT)
Description: Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
Study: NCT03853538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one hemiface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semisolid vaseline
Description: Product is applied to one hemiface.
Study: NCT03870451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuTherm5 vascular compression device
Description: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuTherm5 vascular compression device
Description: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
Study: NCT01406938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150mg
Description: (1 injection per dose) and placebo to secukinumab 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150mg
Description: (1 injection per dose) and placebo to secukinumab 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150mg
Description: (1 injection per dose) and placebo to secukinumab 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300mg
Description: secukinumab 150 mg (2 injections per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300mg
Description: secukinumab 150 mg (2 injections per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300mg
Description: secukinumab 150 mg (2 injections per dose)
Study: NCT04015427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant crown
Description: After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant crown
Description: After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
Study: NCT02186834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
Study: NCT03853538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semisolid vaseline
Description: Product is applied to one hemiface.
Study: NCT03897803

Intervention type: DIAGNOSTIC_TEST
Intervention: strain elastography
Description: strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.

Intervention type: DIAGNOSTIC_TEST
Intervention: strain elastography
Description: strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.

Intervention type: DIAGNOSTIC_TEST
Intervention: strain elastography
Description: strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.

Intervention type: DIAGNOSTIC_TEST
Intervention: strain elastography
Description: strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
Study: NCT00106964

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B 20 mcg
Description: A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B 40 mcg
Description: A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
Description: Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle.
Study: NCT03267563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIAU
Description: Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIAU
Description: Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIAU
Description: Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LICF
Description: Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LICF
Description: Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HICF
Description: Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
Study: NCT02358135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Connected health, (CCH)
Description: CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
Study: NCT03132298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Theories of Personality Program
Description: This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
Study: NCT02358135

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
Study: NCT02955823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab-Dexamethasone-Lenalidomide
Description: 1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity.
Study: NCT03486691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine measurement of left lobe
Description: Routine preoperative measurement of left lobe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: no routine preoperative measurement of left lobe
Study: NCT03855046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 50 U Intramuscular Powder for Solution
Description: Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy.
Description: The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
Study: NCT03206970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm.
Study: NCT03702959

Intervention type: DRUG
Intervention: Betamethasone
Description: Corticosteroids

Intervention type: DRUG
Intervention: Betamethasone
Description: Corticosteroids

Intervention type: DRUG
Intervention: Betamethasone
Description: Corticosteroids

Intervention type: DRUG
Intervention: Betamethasone
Description: Corticosteroids
Study: NCT03230890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRREM
Description: HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
Study: NCT04653922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LinkCor Bioengineered Corneal Implant
Description: Intrastromal implantation of a bioengineered corneal equivalent device
Study: NCT00413894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
Study: NCT01289288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed printed materials and in-office training
Description: 1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients
Study: NCT00374946

Intervention type: DEVICE
Intervention: THA

Intervention type: DEVICE
Intervention: THA

Intervention type: DEVICE
Intervention: THA

Intervention type: DEVICE
Intervention: THA
Study: NCT00289068

Intervention type: PROCEDURE
Intervention: Phacoemulsification Sleeve surgery
Description: Group 2.2 mm surgery setting

Intervention type: PROCEDURE
Intervention: Phacoemulsification Sleeves surgery
Description: Group 2.8 mm surgery setting

Intervention type: PROCEDURE
Intervention: Phacoemulsification Sleeves
Description: Group 3.0 mm surgery setting
Study: NCT01811485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMF237 50/250 mg
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMF237 50/250 mg
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMF237 50/500 mg
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
Study: NCT03558386

Intervention type: BEHAVIORAL
Intervention: ePRO survey
Description: An electronic patient reported outcomes survey will be completed by the patient.
Study: NCT03132298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Program
Description: This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
Study: NCT00116649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod cream
Description: imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
Study: NCT03914092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide injection
Description: ,1 mm percutaneous intralesional injection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smith Accent method of voice therapy
Description: regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
Study: NCT03748186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: intravenous antibody drug conjugate
Study: NCT01688492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.